The rationale and design of Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT): a prospective cohort study of childhood nephrotic syndrome

BMC Nephrology

Rulan S Parekh⁵  Tino D Piscione⁴  Christoph P B Licht⁴  Diane Hebert⁴  Christopher D Battiston¹  Pranali Patel²  Viral P Patel⁴  Tonny M Banh⁴  Jovanka Vasilevska-Ristovska¹  J Anastasia Zello³  Neesha Hussain¹ 

[1] Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, 555 University Avenue, M5G 1X8, Toronto, ON, Canada;Genetic and Genome Biology, Research Institute, The Hospital for Sick Children, 555 University Avenue, M5G 1X8, Toronto, ON, Canada;University of Saskatchewan, 105 Administration Place, S7N 5A2, Saskatoon, SK, Canada;University of Toronto, 27 King’s College Circle, M5S 1A1, Toronto, ON, Canada;Dalla Lana School of Public Health, University of Toronto, 27 King’s College Circle, M5S 1A1, Toronto, ON, Canada

关键词: Study protocol;    Minimal change disease;    FSGS;    Chronic kidney disease;    Cohort;    Nephrotic syndrome;    Children;   

Others  :  1083013
DOI  :  10.1186/1471-2369-14-25

 received in 2012-11-28, accepted in 2013-01-10,  发布年份 2013

【 摘 要 】

Background

Nephrotic syndrome is one of the most commonly diagnosed kidney diseases in childhood and its progressive forms can lead to chronic kidney disease (CKD) and/or end-stage renal disease (ESRD). There have been few longitudinal studies among a multi-ethnic cohort to determine potential risk factors influencing disease susceptibility, treatment response, and progression of nephrotic syndrome. Temporal relationships cannot be studied through cross-sectional study design. Understanding the interaction between various factors is critical to developing new strategies for treating children with kidney disease. We present the rationale and the study design of a longitudinal cohort study of children with nephrotic syndrome, the Insight into Nephrotic Syndrome: Investigating Genes, Health and Therapeutics (INSIGHT) study. The specific aims are to determine: 1) socio-demographic, environmental, and genetic factors that influence disease susceptibility; 2) rates of steroid treatment resistance and steroid treatment dependence, and identify factors that may modify treatment response; 3) clinical and genetic factors that influence disease susceptibility and progression to CKD and ESRD; and 4) the interaction between the course of illness and socio-demographic, environmental, and clinical risk factors.

Methods/design

INSIGHT is a disease-based observational longitudinal cohort study of children with nephrotic syndrome. At baseline, participants complete questionnaires and provide biological specimen samples (blood, urine, and toenail clippings). Follow-up questionnaires and repeat biological specimen collections are performed annually for up to five years.

Discussion

The proposed cohort will provide the structure to test various risk factors predicting or influencing disease susceptibility, treatment response, and progression to CKD among children with nephrotic syndrome.

Trial registration

ClinicalTrials.gov Identifier NCT01605266.

【 授权许可】

   
2013 Hussain et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]ISKDC: Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981, 20(6):765-771.
• [2]Eddy AA, Symons JM: Nephrotic syndrome in childhood. Lancet 2003, 362(9384):629-639.
• [3]Bhimma R, Adhikari M, Asharam K: Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 2006, 21(12):1847-1853.
• [4]Copelovitch L, Sam Ol O, Taraquinio S, Chanpheaktra N: Childhood nephrotic syndrome in Cambodia: an association with gastrointestinal parasites. J Pediatr 2010, 156(1):76-81.
• [5]Ingulli E, Tejani A: Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991, 5(4):393-397.
• [6]Mubarak M, Lanewala A, Kazi JI, Akhter F, Sher A, Fayyaz A, Bhatti S: Histopathological spectrum of childhood nephrotic syndrome in Pakistan. Clin Exp Nephrol 2009, 13(6):589-593.
• [7]Soyka LF: Treatment of the nephrotic syndrome in childhood: Use of an alternate-day prednisone regimen. Arch Pediatr Adolesc Med 1967, 113(6):693-701.
• [8]Bircan Z, Yavuz Yilmaz A, Katar S, Vitrinel A, Yildirim M: Childhood idiopathic nephrotic syndrome in Turkey. Pediatr Int 2002, 44(6):608-611.
• [9]Ozkaya N, Cakar N, Ekim M, Kara N, Akkok N, Yalcinkaya F: Primary nephrotic syndrome during childhood in Turkey. Pediatr Int 2004, 46(4):436-438.
• [10]Kim JS, Bellew CA, Silverstein DM, Aviles DH, Boineau FG, Vehaskari VM: High incidence of initial and late steroid resistance in childhood nephrotic syndrome. Kidney Int 2005, 68(3):1275-1281.
• [11]Chang JW, Tsai HL, Wang HH, Yang LY: Clinicopathological features and prognosis of Chinese children with idiopathic nephrotic syndrome between different age groups. Eur J Pediatr 2009, 168(10):1189-1194.
• [12]Otukesh H, Otukesh S, Mojtahedzadeh M, Hoseini R, Fereshtehnejad SM, Riahi Fard A, Sadigh N, Heshmatzade Behzadi A, Javadi R, Hooman N: Management and outcome of steroid-resistant nephrotic syndrome in children. Iran J Kidney Dis 2009, 3(4):210-217.
• [13]Banaszak B, Banaszak P: The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatr Nephrol 2012, 27(6):927-932.
• [14]Kumar J, Gulati S, Sharma AP, Sharma RK, Gupta RK: Histopathological spectrum of childhood nephrotic syndrome in Indian children. Pediatr Nephrol 2003, 18(7):657-660.
• [15]Wong W: Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Paediatr Child Health 2007, 43(5):337-341.
• [16]El Bakkali L, Rodrigues Pereira R, Kuik DJ, Ket JC, Van Wijk JA: Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature. Pediatr Nephrol 2011, 26(8):1241-1246.
• [17]ISKDC: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981, 98(4):561-564.
• [18]Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children Kidney Int 1978, 13(2):159-165.
• [19]Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008, 40(10):1185-1192.
• [20]Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40(10):1175-1184.
• [21]Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329(5993):841-845.
• [22]Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S: APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. J Am Soc Nephrol 2011, 22(11):2129-2137.
• [23]O'Seaghdha CM, Parekh RS, Hwang S-J, Li M, Köttgen A, Coresh J, Yang Q, Fox CS, Kao WHL: The MYH9/APOL1 region and chronic kidney disease in European-Americans. Hum Mol Genet 2011, 20(12):2450-2456.
• [24]Oleksyk TK, Nelson GW, An P, Kopp JB, Winkler CA: Worldwide distribution of the MYH9 kidney disease susceptibility alleles and haplotypes: evidence of historical selection in Africa. PLoS One 2010, 5(7):e11474.
• [25]George CR: Mercury and the kidney. J Nephrol 2011, 24(Suppl 17):S126-S132.
• [26]Meadow SR, Sarsfield JK: Steroid-responsive and nephrotic syndrome and allergy: clinical studies. Arch Dis Child 1981, 56(7):509-516.
• [27]Jahan I, Hanif M, Ali MA, Waliullah SM, Mia AH: Relationship between serum IgE and frequent relapse idiopathic nephrotic syndrome. Mymensingh medical journal: MMJ 2011, 20(3):484-489.
• [28]Cheung W, Wei CL, Seah CC, Jordan SC, Yap HK: Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol 2004, 19(6):627-632.
• [29]de Burbure C, Buchet JP, Leroyer A, Nisse C, Haguenoer JM, Mutti A, Smerhovsky Z, Cikrt M, Trzcinka-Ochocka M, Razniewska G: Renal and neurologic effects of cadmium, lead, mercury, and arsenic in children: Evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006, 114(4):584-590.
• [30]Vance JC, Fazan LE, Satterwhite B, Pless IB: Effects of nephrotic syndrome on the family: A controlled study. Pediatrics 1980, 65(5):948-955.
• [31]Vance JC, Pless IB: The effect of chronic nephrotic syndrome on the affected child. J Dev Behav Pediatr 1983, 4(3):159-162.
• [32]Naidoo LR, Moodley TY, Coovadia HM, Adhikari M: Neural deficits, intelligence, maladjustment and family response in children with the nephrotic syndrome. Samj S Afr Med J 1987, 71(1):9-10.
• [33]Mehta M, Bagga A, Pande P, Bajaj G, Srivastava RN: Behavior problems in nephrotic syndrome. Indian Pediatr 1995, 32(12):1281-1286.
• [34]Soliday E, Lande MB: Family structure and the course of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2002, 17(1):41-44.
• [35]Soliday E, Moore KJ, Lande MB: Daily reports and pooled time series analysis: Pediatric psychology applications. J Pediatr Psychol 2002, 27(1):67-76.
• [36]Hall AS, Thorley G, Houtman PN: The effects of corticosteroids on behavior in children with nephrotic syndrome. Pediatr Nephrol 2003, 18(12):1220-1223.
• [37]Ruth EM, Landolt MA, Neuhaus TJ, Kemper MJ: Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 2004, 145(6):778-783.
• [38]Guha P, De A, Ghosal M: Behavior profile of children with nephrotic syndrome. Indian Journal of Psychiatry 2009, 51(2):122-126.
• [39]Mitra S, Banerjee S: The impact of pediatric nephrotic syndrome on families. Pediatr Nephrol 2011, 26(8):1235-1240.
• [40]Wright RO, Christiani D: Gene-environment interaction and children's health and development. Curr Opin Pediatr 2010, 22(2):197-201.
• [41]Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WHL, Astor BC, Bottinger EP, Iyengar SK, Klotman PE: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013, 83(1):114-120.
• [42]Varni JW, Seid M, Kurtin PS: PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001, 39(8):800-812.
• [43]Byles J, Byrne C, Boyle MH, Offord DR: Ontario Child Health Study: reliability and validity of the general functioning subscale of the McMaster Family Assessment Device. Fam Process 1988, 27(1):97-104.
• [44]Kroenke K, Spitzer RL, Williams JBW, Lowe B: An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ-4. Psychosomatics 2009, 50(6):613-621.
• [45]Lowe B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, Schneider A, Brahler E: A 4-item measure of depression and anxiety: Validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 2010, 122(1–2):86-95.
• [46]Baker DW, Williams MV, Parker RM, Gazmararian JA, Nurss J: Development of a brief test to measure functional health literacy. Patient Educ Couns 1999, 38(1):33-42.
• [47]Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ: Management of childhood onset nephrotic syndrome. Pediatrics 2009, 124(2):747-757.
• [48]Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J: Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000, 105(6):1242-1249.
• [49]Wilhelm M, Hafner D, Lombeck I, Ohnosorge FK: Monitoring of cadmium, copper, lead and zinc status in young children using toenails: comparison with scalp hair. Sci Total Environ 1991, 103(2–3):199-207.
• [50]Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M, Mahoney L, McCrindle B, Mietus-Snyder M, Steinberger J: Ambulatory blood pressure monitoring in children and adolescents: recommendations for standard assessment: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 2008, 52(3):433-451.
• [51]Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomedical Informatics 2009, 42(2):377-381.
• [52]2008 Best Practices for Respositories: collection, storage, retrieval and distribution of biological materials for research: International Society for Biological and Environmental Repositories (ISBER) Cell Preserv Technol 2008, 6(1):5+.
• [53]Canada S: Low Income Lines, 2010 to 2011. Edited by Industry. Ottawa: Authority of the Minister Responsible for Statistics Canada; 2012:28-30. Volume 75F0002M
• [54]Otukesh H, Ghazanfari B, Fereshtehnejad SM, Bakhshayesh M, Hashemi M, Hoseini R, Chalian M, Salami A, Mehdipor L, Rahiminia A: NPHS2 mutations in children with steroid-resistant nephrotic syndrome. Iran J Kidney Dis 2009, 3(2):99-102.
• [55]Hinkes BGMB, Vlangos CN, Gbadegsin R, Liu J, Hasselbacher K, Hangan D, Ozaltin F, Zenker M, Hildebrandt and members of the Arbeitsgemeinschaft fur Paediatrische Nephologie Study Group: Nephrotic Syndrome in the First Year of life: Two Thirds of Cases are Caused by Mutations in 4 Genes (NPHS1, NPHS2, WT1 and LAMB2). Paediatrics Int 2007, 119(4):907-919.
• [56]Murray P, Chune G, Raghavan V: Legacy Effects from DCCT and UKPDS: What They Mean and Implications for Future Diabetes Trials. Curr Atheroscler Rep 2010, 12(6):432-439.
• [57]Genuth S, Nathan D, Shamoon H, Duffy H, Dahms B, Mayer L, Brillion D, Lackaye M, Whitehouse F, Kruger D: Epidemiology of Diabetes Interventions and Complications (EDIC): Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999, 22(1):99-111.
• [58]Copelovitch L, Warady BA, Furth SL: Insights from the Chronic Kidney Disease in Children (CKiD) Study. Clin J Am Soc Nephrol 2011, 6(8):2047-2053.
• [59]Clinical Registry of SRNS Patients. : ; http://www.podonet.org/opencms/opencms/podonet/podonet_en/PodoNet_Projects/Clinical_Registry_Of_SRNS_Patients.html webcite
• [60]RaDaR : ; www.renalradar.org webcite
• [61]Nephrotic Syndrome Study Network. : ; https://rarediseasesnetwork.epi.usf.edu/NEPTUNE/index.htm webcite
• [62]Cukor D, Cohen SD, Peterson RA, Kimmel PL: Psychosocial Aspects of Chronic Disease: ESRD as a Paradigmatic Illness. J Am Soc Nephrol 2007, 18(12):3042-3055.
• [63]Barlow JH, Ellard DR: The psychosocial well-being of children with chronic disease, their parents and siblings: an overview of the research evidence base. Child Care Health Dev 2006, 32(1):19-31.